Casdin Capital’s 2seventy bio TSVT Stock Holding History

Casdin Capital’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,000,000	Closed	-$9.88M	–	43
2025 Q1	$9.88M	Hold	2,000,000	–	–	0.81%	22
2024 Q4	$5.88M	Hold	2,000,000	–	–	0.39%	28
2024 Q3	$9.44M	Hold	2,000,000	–	–	0.63%	22
2024 Q2	$7.7M	Hold	2,000,000	–	–	0.59%	24
2024 Q1	$10.7M	Buy	2,000,000 +817,377	+69%	+$3.84M	0.8%	23
2023 Q4	$5.05M	Sell	1,182,623 -841,290	-42%	-$2.59M	0.5%	27
2023 Q3	$7.93M	Hold	2,023,913	–	–	0.88%	24
2023 Q2	$20.5M	Hold	2,023,913	–	–	1.79%	19
2023 Q1	$20.6M	Buy	2,023,913 +173,913	+9%	+$1.99M	1.7%	17
2022 Q4	$17.3M	Buy	1,850,000 +1,235,246	+201%	+$17.4M	1.34%	20
2022 Q3	$8.95M	Hold	614,754	–	–	0.59%	25
2022 Q2	$8.12M	Hold	614,754	–	–	0.69%	25
2022 Q1	$10.5M	Buy	+614,754	New	+$10.4M	0.47%	33

Other funds holding TSVT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Casdin Capital's TSVT Position: Q2 2025 in Review

Casdin Capital sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 2,000,000 shares — an estimated $9.88M sold.

Casdin Capital first reported a position in TSVT in Q1 2022 and held it in 13 quarters. The position peaked at $20.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

Casdin Capital reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
Casdin Capital sold 2,000,000 2seventy bio shares in Q2 2025, an estimated $9.88M.
Casdin Capital first reported a position in 2seventy bio in Q1 2022 and held it in 13 quarters.
Casdin Capital's 2seventy bio position peaked at $20.6M in Q1 2023.
2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.